1421503-38-9

Basic information

• Product Name: 4-BROMO-5-ETHYL-2-FLUOROPHENOL
• Synonyms: 4-BROMO-5-ETHYL-2-FLUOROPHENOL;EOS-60407
• CAS NO: 1421503-38-9
• Molecular Formula: C₈H₈BrFO
• Molecular Weight: 219.0509232
• Mol File: 1421503-38-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-BROMO-5-ETHYL-2-FLUOROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-5-ETHYL-2-FLUOROPHENOL(1421503-38-9)
• EPA Substance Registry System: 4-BROMO-5-ETHYL-2-FLUOROPHENOL(1421503-38-9)

Safety Data

• Hazardous Substances Data: 1421503-38-9(Hazardous Substances Data)

Usage

General Description

4-Bromo-5-ethyl-2-fluorophenol is a chemical compound with the molecular formula C8H8BrFO. It is a phenolic compound with a bromine and fluorine atom attached to a benzene ring, along with an ethyl group. This chemical is used in the synthesis of pharmaceuticals, agrochemicals, and organic compounds. It has potential applications in the pharmaceutical industry as an intermediate in the production of drugs and medications. Additionally, it has been studied for its antimicrobial and antifungal properties, and its use as a reagent in chemical reactions. Overall, 4-Bromo-5-ethyl-2-fluorophenol is a versatile compound with potential applications in various industries.

Upstream product

• 459-47-2 1-ethyl-4-fluorobenzene 
• 112204-58-7 5-Bromo-2-fluorophenol 
• 891843-05-3 5-ethyl-2-fluoro-phenol 

Downstream Products

• 1421503-40-3 (2-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-ethyl-phenoxy]methoxy}ethyl)(trimethyl)silane 
• 1421503-41-4 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carbonitrile 
• 1421503-42-5 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidic acid methyl ester 
• 1421503-43-6 N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine 
• 1421503-44-7 4,4-diethoxy-3-{[6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidoyl]amino}piperidine-1-carboxylic acid tert-butyl ester 
• 1421502-61-5 N-(1-benzyl-4,4-diethoxy-piperidin-3-yl)-6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboxamidine 
• 1421503-39-0 (2-((4-bromo-5-ethyl-2-fluorophenoxy)methoxy)ethyl)-trimethylsilane 

Relevant articles and documents

Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism

The Janus family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) play an essential role in the receptor signaling of cytokines that have been implicated in the pathogenesis of severe asthma, and there is emerging interest in the development of small-molecule-inhaled JAK inhibitors as treatments. Here, we describe the optimization of a quinazoline series of JAK inhibitors and the results of mouse lung pharmacokinetic (PK) studies where only low concentrations of parent compound were observed. Subsequent investigations revealed that the low exposure was due to metabolism by aldehyde oxidase (AO), so we sought to identify quinazolines that were not metabolized by AO. We found that specific substituents at the quinazoline 2-position prevented AO metabolism and this was rationalized through computational docking studies in the AO binding site, but they compromised kinome selectivity. Results presented here highlight that AO metabolism is a potential issue in the lung.

Design and synthesis of a Pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin

By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.